我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

阻断PPARβ/δ途径对阿托伐他汀抑制衰老心肌细胞中MMP-9表达的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第6期
页码:
633-636
栏目:
基础研究
出版日期:
2013-11-25

文章信息/Info

Title:
Effect of blocking PPARβ/δ signal channel on atorvastatin in inhibiting MMP9 expression in aging cardiomyocytes
作者:
韩 磊1; 叶 平2; 李鸣皋1
(1.解放军海军总医院全军航海航空医学中心，北京 100048；2.解放军总医院老年心血管二科，北京 100853)
Author(s):
HAN Lei1;  YE Ping2;  LI Minggao1
(1.Aviation and Nautical Medical Center, PLA Navy General Hospital, Beijing 100048, China; 2.Second Department of Geriatric Cardiology, PLA General Hospital, Beijing 100853, China)
关键词:
阿托伐他汀; 过氧化物酶增殖物激活型受体β/δ; 基质金属蛋白酶-9; 心肌细胞; 衰老大鼠
Keywords:
atorvastatin;  peroxisome proliferator activated receptor β/δ;  matrix metalloproteinase9;  cardiomyocytes;  aging rat
分类号:
R972.6
DOI:
-
文献标识码:
A
摘要:
目的:观察阻断过氧化物酶增殖物激活型受体β/δ（peroxisome proliferator activated receptor β/δ，PPARβ/δ）信号通路对阿托伐他汀抑制老年大鼠心肌细胞基质金属蛋白酶9（matrix metalloproteinase-9，MMP-9）表达的影响。方法:分离培养24个月龄大鼠的心肌细胞,将培养的心肌细胞分为空白对照组、溶剂对照组、阿托伐他汀组及PPARβ/δ拮抗剂GSK0660+阿托伐他汀组，4组细胞依次分别加入细胞培养液、二甲基亚砜（dimethyl sulfoxide，DMSO）、阿托伐他汀及阿托伐他汀+GSK0660处理。用RT-PCR方法检测各组大鼠心肌细胞中MMP-9 mRNA表达水平，用Western blot方法检测各组大鼠心肌细胞的MMP-9蛋白的含量。结果：①与空白对照组相比，溶剂对照组大鼠心肌细胞中MMP-9 mRNA表达水平和其蛋白含量均无显著差异，阿托伐他汀组心肌细胞中MMP-9 mRNA表达水平和其蛋白含量均显著降低（P<0.01）；②GSK0660+阿托伐他汀组心肌细胞中MMP-9 mRNA表达水平及其蛋白含量均显著高于阿托伐他汀组（P<0.05或P<0.01），但仍低于空白对照组（P<0.05）。结论:阿托伐他汀可激活PPARβ/δ信号通路下调衰老心肌细胞中MMP9的表达。
Abstract:
AIM:To investigate the effect of blocking peroxisome proliferator activated receptor β/δ (PPARβ/δ) signal channel on the action of atorvastatin in inhibiting matrix metalloproteinase9 (MMP-9) expression in cardiomyocytes of aging rats. METHODS: Primary cardiomyocytes were cultured in aging rats. Cardiomyocytes were divided into control group, dimethyl sulfoxide (DMSO) group, atorvastatin group and atorvastatin plus GSK0660 group, which were treated by cell culture medium, DMSO, atorvastatin, and atorvastin plus GSK0660, respectively. Expression of MMP-9 mRNA was evaluated by RTPCR and the content of MMP-9 protein was detected by Western blot. RESULTS: No difference was observed in the expression level of MMP-9 mRNA and protein between control group and DMSO group. Expression level of MMP-9 mRNA and MMP-9 protein in atorvastatin group was significantly lower than in control group (P<0.01). Both mRNA and protein expression levels of MMP-9 in atorvastatin plus GSK0660 group were higher than in atorvastatin group (P<0.05 or P<0.01) but still lower than those in control group (P<0.05). CONCLUSIONS: Atorvastatin downregulates the expression of MMP-9 in aging cardiomyocytes by activating PPARβ/δ signal channel.

参考文献/References

[1]Takano H,Komuro I.Peroxisome proliferator activated receptor gamma and cardiovascular diseases[J].Circ J,2009,73(2):214-220.
[2]Nunn AVW,Bell J,Barter P.The integration of lipidsensing and antiinflammatory effects:how the PPARs play a role in metabolic balance[J].Nucl Recept,2007,5(1):1-13.
[3]Yamamoto K,Ohki R,Lee RT,et al.Peroxisome proliferatoractivated receptor γ activators inhibit cardiac hypertrophy in cardiac myocyte[J].Circulation,2001,104(14):1670-1675.
[4]Pascual G,Mendieta C,García HN,et al.TGFbeta1 upregulation in the aging varicose vein[J].J Vasc Res,2006,17(12):3315-3324.
[5]Wang M,Takagi G,Asai K,et al.Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates[J].Hypertension,2003,41(6):1308-1316.
[6]Nakano Y,Niida S,Dote K,et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation[J].J Am Coll Cardiol,2004,43(5):818-825.
[7]Blankenberg S,Rupprecht HJ,Poirier O,et al.Plasma concentrations and genetic variation of matrixmetalloproteinase 9 and prognosis of patients with cardiovascular disease[J].Circulation,2003,107(12): 1579-1585.
[8]Lalu MM,Pasini E,Schulze CJ,et al.Ischemiareperfusion injury activates matrix metalloproteinases in the human heart[J].Eur Heart J,2005,26(1):27-35.
[9]Delgado MA,Zamorano JL.Atorvastatin calcium plus amlodipine for the treatment of hypertension[J].Expert Opin Pharmacother,2012,13(18):2673-2685.
[10]Kotlega D,Ciec′wiez S,TurowskaKJ,et al.Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis[J]. Neurol Neurochir Pol,2012,46(2):176-183.
[11]Padhy BM,Yadav R,Gupta YK,et al. Hypolipidaemic and anti inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia[J].Singapore Med J,2013,54(2):90-95.
[12]Kotlega D,Ciec′wiez S,TurowskaKowalska J,et al.Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis[J].Neurol Neurochir Pol,2012,46(2):176-183.
[13]盛 莉, 叶 平,刘永学.阿托伐他汀上调过氧化物酶体增殖物活化型受体α、γ表达及抑制心肌细胞肥大的作用[J].中华心血管病杂志,2005,33(12):1080-1084.
[14]Cui JJ,Wang D,Gao F,et al.Effects of atorvastatin on pathological changes in brain tissue and plasma MMP-9 in rats with intracerebral hemorrhage[J].Cell Biochem Biophys,2009,62(1):87-90.

备注/Memo

备注/Memo:
收稿日期：2013-03-29.基金项目：国家自然科学基金项目资助（70872713） 通讯作者：李鸣皋，主任医师，主要从事老年心血管与航海航空医学研究 Email：namc2011@sina.com 作者简介：韩磊，主治医师，博士 Email：leihan999@sina.com
更新日期/Last Update: 2013-11-20